Standards for clinical trials in sexual dysfunction in women: Research designs and outcomes assessment

Journal of Sexual Medicine

Volumn 7, Issue 1 PART 2, 2010, Pages 541-560

  Clayton, Anita H ^a   Dennerstein, Lorraine ^b   Fisher, William A ^c   Kingsberg, Sheryl A ^d   Perelman, Michael A ^e   Pyke, Robert E ^f  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

Female sexual dysfunction; FSD, clinical trials; Research design

Indexed keywords

BREMELANOTIDE; FLIBANSERIN; PLACEBO; SILDENAFIL; TESTOSTERONE; TIBOLONE;

ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL; DISEASE SEVERITY; DISTRESS SYNDROME; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; FEMALE SEXUAL DYSFUNCTION; HUMAN; HYPOACTIVE SEXUAL DESIRE DISORDER; MEDICAL ETHICS; OUTCOME ASSESSMENT; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; SEXUAL AROUSAL DISORDER; STANDARD;

EID: 74049120718     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2009.01628.x     Document Type: Article

References (63)

1. FDA Draft Guidance on Patient Reported Outcomes. US Department of Health and Human Services: Food and Drug Administration. 2006, February
2. Derogatis LR. Assessment of sexual function/dysfunction via patient reported outcomes. Int J Impot Res 2008, 20:35-44.
3. Derogatis LR, Burnett AL. Key methodologic issues in sexual medicine research. J Sex Med 2007, 4:527-37.
4. Clayton AH, Jolly E, Thorp J, Lewis-D'Agostino DJ, Wunderlich G, Lesko L. Baseline characteristics of patients enrolled in three Phase III North American trials of flibanserin in premenopausal women with hypoactive sexual desire disorder. Poster Presentation. 2009 Annual Meeting of the International Society for the Study of Women's Sexual Health (ISSWSH), Florence, Italy, February 2009
5. 2006, http://www.emea.europa.eu/humandocs/Humans/EPAR/intrinsa/intrinsa.htm, European Public Assessment Report for Intrinsa, Available at: (accessed December 8, 2009
6. Shames D, Monroe SE, Davis D, Soule L. Regulatory perspective on clinical trials and end points for female sexual dysfunction, in particular, hypoactive sexual desire disorder: Formulating recommendations in an environment of evolving clinical science. Int J Impot Res 2007, 19:30-6.
7. Rosen RC, Brewer JV, Gerstenberger EP, Meston CM, Brotto LA, Wiegel M, Sand M. Validation of the FSFI sexual desire domain diagnostic cut-point in predicting HSDD: Independent replication and confirmation. Poster 34, 3rd International Consultation on Sexual Medicine, July 10-3, 2009, Paris, France
8. Sand M, Rosen R, Meston C, Brotto L. The Female Sexual Function Index (FSFI): A potential " gold standard" measure for assessing sexual function in women. Poster 24, 3rd International Consultation on Sexual Medicine, Paris, July 10-3, 2009
9. Rosen RC, Gerstenberger EP, Meston CM, Brotto LA, Wiegel M, Sand M. Criterion validity of the sexual desire domain of the Female Sexual Function Index (FSFI): Identifying a diagnostic cut-point for differentiating women with and without HSDD. Poster 33, 3rd International Consultation on Sexual Medicine, Paris, July 10-3, 2009
10. Rosen RC, Brewer JV, Gerstenberger EP, Meston CM, Brotto LA, Wiegel M, Sand M. Validation of the FSFI sexual desire domain diagnostic cut-point in predicting HSDD: Independent replication and confirmation. Poster 34, 3rd International Consultation on Sexual Medicine, Paris, July 10-3, 2009
11. Revicki D, Margolis MK, Safikhani S, Hanes V. Content validity of the Female Sexual Function Index in pre-menopausal women with hypoactive sexual desire disorder. Poster 44, 3rd International Consultation on Sexual Medicine, July 10-3, 2009, Paris, France
12. Revicki D, Margolis MK, Bush EN, Hanes V. Content validity of the Female Sexual Function Index in pre- and postmenopausal women with hypoactive sexual desire disorder. Poster 45, 3rd International Consultation on Sexual Medicine, July 10-3, 2009, Paris, France
13. Janssen E, Wiedermann MW, Whitley BE. Psychophysiological measurement of sexual arousal. Handbook for conducting research on human sexuality 2002, 139-72. In, eds., Mahwah, NJ, Erlbaum
14. Rosen R, Beck JG. Patterns of sexual arousal 1988, New York, New Guildford
15. Laan E, Everaed W. Determinants of female sexual arousal: Psychophysiological theory and data. Annual Rev Sex Res 1995, 6:32-76.
16. Morokoff PJ. Volunteer bias in the psychophysiological study of female sexuality. J Sex Res 1986, 22:35-51.
17. Rellini AH, McCall KM, Randall PK, Meston CM. The relationship between women's subjective and physiological sexual arousal. Psychophysiology 2005, 42:116-24.
18. Davis SR, Davison SL, Donath S, Bell RJ. Circulating androgen levels and self-reported sexual function in women. JAMA 2005, 294:91-6.
19. Davis SR, Moreau M, Kroll R, Bouchard C, Panay N, Gass M, Braunstein G, Hirschberg AL, Rodenberg C, Pack S, Koch H, Moufarege A, Studd J. Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med 2008, 359:2005-17.
20. Shifren JL, Davis SR, Moreau M, Waldbaum A, Bouchard C, DeRogatis L, Derzko C, Bearnson P, Kakos N, O'Neill S, Levine S, Wekselman K, Buch A, Rodenberg C, Kroll R. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study. Menopause 2007, 13:770-9.
21. Van Anders SM, Chernick AB, Chernick BA, Hampson E, Fisher WA. Preliminary clinical experience with androgen administration for pre- and postmenopausal women with hypoactive sexual desire. J Sex Marital Ther 2005, 31:173-85.
22. Simon J, Braunstein G, Nachtigall L, Utian W, Katz M, Miller S, Waldbaum A, Bouchard C, Derzko C, Buch A, Rodenberg C, Lucas J, Davis S. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab 2005, 90:5226-33.
23. Panzer C, Wise S, Fantini G, Kang D, Munarriz R, Guay A, Goldstein I. Impact of oral contraceptives on sex hormone-binding globulin and androgen levels: A retrospective study in women with sexual dysfunction. J Sex Med 2006, 3:104-13.
24. Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, Ferguson D, D'Agostino R. The Female Sexual Function Index (FSFI): A multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 2000, 26:191-208.
25. Quirk FH, Heiman JR, Rosen RC, Laan E, Smith MD, Boolell M. Development of a sexual function questionnaire for clinical trials of female sexual dysfunction. J Women's Health Gen Med 2002, 11:277-89.
26. Derogatis L, Rust J, Golombok S, Bouchard C, Nactigall L, Rodenberg C, Kuznicki J, McHorney C. Validation of the Profile of Female Sexual Function (PFSF) in surgically and naturally menopausal women. J Sex Marital Ther 2004, 30:25-36.
27. Ter Kuile MM, Brauer M, Laan E. The Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale (FSDS): Psychometric properties within a Dutch population. J Sex Marital Ther 2006, 32:289-304.
28. Oksuz E, Malhan S. Reliability and validity of the female sexual function index in the Turkish population. Aile Hekimligi 2005, 17:54-60.
29. Derogatis L, Rosen R, Leiblum S, Burnett A, Heiman J. The Female Sexual Distress Scale (FSDS): Initial validation of a standardized scale for assessment of sexually related personal distress in women. J Sex Marital Ther 2002, 28:317-30.
30. Derogatis L, Clayton A, lewis-D" Agostino D, Wunderlich G, Fu Y. Validation of the Female Sexual Distress Scale-Revised for assessing distress in women with hypoactive sexual desire disorder. J Sex Med 2008, 5:357-64.
31. Hayes RD, Dennerstein L, Bennett CM, Sidat M, Gurrin L, Fairley CK. Risk factors for female sexual dysfunction in the general population: Exploring factors associated with low sexual function and sexual distress. J Sex Med 2008, 5:1681-93.
32. Dennerstein L, Koochaki P, Barton I, Graziottin A. Hypoactive sexual desire disorder in menopausal women: A survey of western European women. J Sex Med 2006, 3:212-22.
33. Hayes R, Dennerstein L, Bennett C, Koochaki P, Leiblum S, Graziottin A. relationship between hypoactive sexual desire disorder and aging. Fertil Steril 2007, 87:107-12.
34. Hayes RD, Dennerstein L, Bennett CM, Fairley CK. What is the true prevalence of female sexual dysfunction and does the way we assess these conditions have an impact? J Sex Med 2008, 5:777-87.
35. Dennerstein L, Guthrie JR, Hayes RD, Derogatis LR, Lehert P. Sexual function, dysfunction and sexual distress in a prospective, population-based sample of mid-aged Australian-born women. J Sex Med 2008, 5:2291-9.
36. Pyke R, Goldfischer ER, Mikl J. The ROSE Study: Placebo-controlled, randomized withdrawal trial of flibanserin for hypoactive sexual desire disorder in premenopausal women. Poster presentation. American Psychiatric Association Institute for Psychiatric Services annual meeting 2007, New Orleans, LA, October 11
37. Althof SE, Dean J, Derogatis LR, Rosen RC, Sisson M. Current perspectives on the clinical assessment and diagnosis of female sexual dysfunction and clinical studies of potential therapies: A statement of concern. J Sex Med 2005, 2(3):147-54. suppl
38. Symonds T, Spino C, Sisson M, Soni P, Martin M, Gunter L, Patrick DL. Methods to determine the minimum important difference for a sexual event diary used by postmenopausal women with hypoactive sexual desire disorder. J Sex Med 2007, 4:1328-35.
39. Michalak EE, Murray G, Wilkinson C, Dowrick C, Lam RW. A Pilot study of adherence with light treatment for seasonal affective disorder. Psychiatry Res 2007, 149:315-20.
40. Fisher WA, Rosen RC, Mollen M, Borck G, Karlin G, Pommerville P, Goldstein I, Bangerter K, Bandel TJ, Derogatis LR, Sand M. Improving the sexual quality of life of couples affected by erectile dysfunction: A double-blind, randomized, placebo-controlled trial of vardenafil. J Sex Med 2005, 5:699-708.
41. Cayan S, Bozlu M, Canpolat B, Akbay E. The assessment of sexual functions in women with male partners complaining of erectile dysfunction: Does treatment of male sexual dysfunction improve female partner's sexual functions? J Sex Marital Ther 2004, 30:333-41.
42. Revicki D, Howard K, Hanlon J, Mannix S, Greene A, Rothman M. Characterizing the burden of premature ejaculation from a patient and partner perspective: A multi-country qualitative analysis. Health Qual Life Outcomes 2008, 6:33. http://www.hqlo.com/content/6/1/33
43. 4th. Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Association, edition (DSM-IV, Washington, DC, American Psychiatric Association
44. Wiegel M, Meston C, Rosen R. The Female Sexual Function Index (FSFI): Cross validation and development of clinical cutoff scores. J Sex Marital Ther 2005, 31:1-20.
45. Caruso S, Rugolo S, Agnello C, Intelisano D, DiMari L, Cianci A. Sildenafil improves sexual functioning in premenopausal women with type 1 diabetes who are affected by sexual arousal disorder: A double-blind, crossover, placebo-controlled pilot study. Fertil Steril 2006, 85:1496-501.
46. Berman JR, Berman LA, Toler SM, Gill J, Haughie S. Safety and efficacy of sildenafil citrate for the treatment of female sexual arousal disorder: A double-blind, placebo-controlled study. J Urol 2003, 170:2333-8.
47. Basson R, McInnes R, Smith MD, Hodgson G, Koppiker N. Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder. J Womens Health Gend Based Med 2002, 11:367-77.
48. Caruso S, Intelisano G, Lupo L, Agnello C. Premenopausal women affected by sexual arousal disorder treated with sildenafil: A double-blind, cross-over, placebo-controlled study. BJOG 2001, 108:623-8.
49. Shadish WR, Cook TD, Campbell DT. Experimental and quasi-experimental designs for generalized causal inference 2002, Boston, Houghton Mifflin
50. Goodwin M, Ruhland L, Casson I, MacDonald S, Delva D, Birtwhistle R, Lam M, Seguin R. Pragmatic controlled clinical trials in primary care: The struggle between external and internal validity. BMC Med Res Methodol 2003, 3:28.
51. Rothwell PM. External validity of randomized controlled trials: " To whom do the results of this trial apply? Lancet 2005, 365:82-93.
52. Goldstein I, Fisher WA, Sand M, Rosen R, Mollen M, Brock G, Karlin G, Pommerville P, Bangerter K, Bandel TJ, Derogatis LR. Women's sexual function improves when partners are administered vardenafil for erectile dysfunction: A prospective, randomized, double-blind, placebo-controlled trial. J Sex Med 2005, 2:819-32.
53. Fisher WA, McIntyre-Smith A, Sand M, Carson C, Kirby R, Goldstein I. Erectile dysfunction: The couple context. Textbook of erectile dysfunction 2008, 190-200. In, eds., 2nd, edition, London, Informa
54. Rubio-Auroioles E, Kim ED, Rosen RC, Porst H, Burns P, Zeigler H, Wong DG. Impact on erectile function and sexual quality of life of couples: A double-blind, randomized, placebo-controlled trial of tadalafil taken once daily. J Sex Med 2009, 6:1314-23.
55. Safarinejad MR. Evaluation of the safety and efficacy of bremelanotide, a melanocortin receptor agonist, in female subjects with arousal disorder: A double-blind, placebo-controlled, fixed dose, randomized study. J Sex Med 2008, 5:887-97.
56. Jolly E, Clayton AH, Thorp J, Kimura T, Sand M, Pyke R. Efficacy of flibanserin 100 mg qhs as a potential treatment for Hypoactive Sexual Desire Disorder In North American premenopausal women. Manuscript in preparation. 2009
57. Shifren JL, Braunstein GD, Simon JA, Casson PR, Buster JE, Redmond GP, Burki RE, Ginsburg ES, Rosen RC, Leiblum SR, Caramelli KE, Mazer NA. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000, 343:682-8.
58. Kingsberg S, Shifren J, Wekselman K, Rodenberg C, Koochaki P, DeRogatis L. Evaluation of the clinical relevance of benefits associated with transdermal testosterone treatment in postmenopausal women with hypoactive sexual desire disorder. J Sex Med 2007, 4:1001-8.
59. Davis S, Papalia MA, Norman RJ, O'Neill S, Redelman M, Williamson M, Stuckey BG, Wlodarczyk J, Gardner K, Humberstone A. Safety and efficacy of a testosterone metered-dose transdermal spray for treating decreased sexual satisfaction in premenopausal women: A randomized trial. Ann Intern Med 2008, 148:569-77.
60. Schwenkhagen A, Studd J. Role of testosterone in the treatment of hypoactive sexual desire disorder. Maturitas. 2009, 63:152-9.
61. Campbell DT, Overman ES. Methodology and epistemology for social sciences. Selected papers 1988, In, ed., Chicago, University of Chicago Press
62. Clayton AH, Pradko JF, Croft HA, Montano CB, Leadbetter RA, Bolden-Watson C, Bass KI, Donahue R, Jamerson BD, Metz A. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psych 2002, 63:357-66.
63. Clayton AH, Goldfischer ER, Goldstein I, DeRogatis L, Lewis-D'Agostino DJ, Pyke R. Validation of the Decreased Sexual Desire Screener (DSDS): A brief diagnostic instrument for generalized acquired female hypoactive sexual desire disorder (HSDD). J Sex Med 2009, 6:730-8.